Drug maker Abbvie may have to defend the price of its Humira treatment before the U.S. Senate Finance Committee today.
Category: NYSE:ABBV
Leadership In An Age Of Disruption: Q&A With Abbott Chairman And CEO Miles White
Transformational Business Leaders Interview Series: Miles D. White, Chairman and CEO Abbott Laboratories, the 6th longest tenured CEO among the S&P 100. Under his leadership, he has created approximately $200 billion in shareholder value.
Lessons From The Biggest Pharma Drug Launches Of All Time
But given the medical breakthroughs being made, it is likely that in the coming years there will be new entries in this list – and high priced ones at that.
After 20 Years, Abbott Labs CEO Miles White Has Successor In Mind
Abbott Laboratories CEO Miles White appears to have settled on his successor at the diversified healthcare company in medical device business head Robert Ford.
Why Big Pharma Quietly Cheers Rahm Emanuel’s Exit As Chicago’s Mayor
Rahm Emanuel’s decision to not run again for Mayor of Chicago next year may be good news for the pharmaceutical industry, which has become a target during his tenure.
Why Aren’t Prison Inmates With Hepatitis C Being Treated?
As a matter of general health policy, states should aggressively treat hepatitis C in prisons.
Did Pfizer Blink And What Will Pharma Do Now?
Pfizer confirmed that time has run out for raising prices without blow-back. The renewed attention to drug price hikes means business as usual has ended and two questions loom large for Pharma. Is talk of regulation of drug prices next and who will ne…
